Wuhan Keqian BiologyLtd Past Earnings Performance
Past criteria checks 2/6
Wuhan Keqian BiologyLtd has been growing earnings at an average annual rate of 1.4%, while the Pharmaceuticals industry saw earnings growing at 9.1% annually. Revenues have been growing at an average rate of 9.6% per year. Wuhan Keqian BiologyLtd's return on equity is 7.7%, and it has net margins of 33.2%.
Key information
1.4%
Earnings growth rate
-3.5%
EPS growth rate
| Pharmaceuticals Industry Growth | 10.9% |
| Revenue growth rate | 9.6% |
| Return on equity | 7.7% |
| Net Margin | 33.2% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
The Market Lifts Wuhan Keqian Biology Co.,Ltd (SHSE:688526) Shares 38% But It Can Do More
Oct 09
These 4 Measures Indicate That Wuhan Keqian BiologyLtd (SHSE:688526) Is Using Debt Reasonably Well
Sep 26Investors Continue Waiting On Sidelines For Wuhan Keqian Biology Co.,Ltd (SHSE:688526)
Aug 20We Think Wuhan Keqian BiologyLtd (SHSE:688526) Can Stay On Top Of Its Debt
Jun 26Wuhan Keqian Biology Co.,Ltd (SHSE:688526) Stock Rockets 25% But Many Are Still Ignoring The Company
Apr 08Analysts Are More Bearish On Wuhan Keqian Biology Co.,Ltd (SHSE:688526) Than They Used To Be
Apr 05Earnings Miss: Wuhan Keqian Biology Co.,Ltd Missed EPS By 25% And Analysts Are Revising Their Forecasts
Apr 03Wuhan Keqian BiologyLtd (SHSE:688526) Has A Rock Solid Balance Sheet
Mar 20Revenue & Expenses Breakdown
How Wuhan Keqian BiologyLtd makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 902 | 299 | 244 | 85 |
| 30 Jun 24 | 933 | 309 | 270 | 85 |
| 31 Mar 24 | 989 | 348 | 281 | 87 |
| 31 Dec 23 | 1,064 | 396 | 298 | 89 |
| 30 Sep 23 | 1,142 | 484 | 259 | 100 |
| 30 Jun 23 | 1,139 | 490 | 252 | 100 |
| 31 Mar 23 | 1,078 | 454 | 253 | 100 |
| 31 Dec 22 | 1,001 | 410 | 230 | 103 |
| 30 Sep 22 | 1,014 | 468 | 212 | 90 |
| 30 Jun 22 | 952 | 444 | 190 | 88 |
| 31 Mar 22 | 987 | 493 | 183 | 83 |
| 31 Dec 21 | 1,103 | 571 | 211 | 80 |
| 30 Sep 21 | 1,015 | 514 | 209 | 75 |
| 30 Jun 21 | 1,033 | 551 | 210 | 72 |
| 31 Mar 21 | 987 | 524 | 200 | 68 |
| 31 Dec 20 | 843 | 448 | 160 | 59 |
| 30 Sep 20 | 723 | 371 | 155 | 52 |
| 30 Jun 20 | 576 | 271 | 131 | 45 |
| 31 Mar 20 | 539 | 258 | 124 | 45 |
| 31 Dec 19 | 508 | 243 | 124 | 47 |
| 31 Dec 18 | 735 | 389 | 153 | 48 |
| 31 Dec 17 | 633 | 320 | 115 | 53 |
| 31 Dec 16 | 390 | 186 | 75 | 22 |
Quality Earnings: 688526 has high quality earnings.
Growing Profit Margin: 688526's current net profit margins (33.2%) are lower than last year (42.3%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 688526's earnings have grown by 1.4% per year over the past 5 years.
Accelerating Growth: 688526's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 688526 had negative earnings growth (-38.1%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (-2.5%).
Return on Equity
High ROE: 688526's Return on Equity (7.7%) is considered low.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/26 22:20 |
| End of Day Share Price | 2024/12/26 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Wuhan Keqian Biology Co.,Ltd is covered by 10 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Xie Zhiyou | China Galaxy Securities Co., Ltd. |
| Junhao Fan | China International Capital Corporation Limited |
| Siyang Wang | China International Capital Corporation Limited |